

Product datasheet for **KN402921**

Presenilin 2 (PSEN2) Human Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	Presenilin 2
Locus ID:	5664



[View online »](#)

Components:
KN402921G1, Presenilin 2 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

KN402921G2, Presenilin 2 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

KN402921D, Linear donor DNA containing LoxP-EF1a-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1a-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCTGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCGAG AAGTTGGGG GAGGGGTGCG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGTAAC TGGAAAGTG ATGTCGTGTA CTGGCTCCG CTTTTCCCG AGGGTGGGG AGAACCGTAT
ATAAGTCAG TAGTCGCCG GAACGTTCT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCT GGCCTCTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTG TGCTTGAGT GAGGCCTGCC CTGGGCGTG GGGCCCGCG GTGCGAATCT
GGTGGCACCT TCGCGCCTG CTCGCTGCT TCGATAAGT TCTAGCCATT TAAAATTTT GATGACCTGC
TGCAGCGCT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTCGGTT
TTTGGGGCG CGGGCGGCA CGGGGCCCG GCGTCCCAGC GCACATGTTC GGCAGGCGG GGCCTGCGAG
CGCGCCACC GAGAATCGGA CGGGGTAGT CCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCGCCCT GGGCGCAAG GCTGGCCCG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGCGCTC GGGAGAGCG GCGGGTGAAGT
CACCCACACA AAGGAAAAG GCCTTCCGT CCTCAGCCG CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCGTCAGG CACCTCGAT AGTTCTGAG CTTTGGAGT ACGTCGTCT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTCCCCA CACTGAGTG GTGAGACTG AAGTTAGGCC AGCTTGGCAG CTTGATGTAAT
TCTCCTTGG AATTGCCCT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGC TACGGCTTCT ACCACTTCG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGCTACG CTACGAGGC GGCCGCGTA TCGGCGACT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTG ATGGCAGCT CACCCGACC TTCAGCCTG GCGACGGCG CTACTACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGC ATCGTGGAGT ACCAGCACG CTTCAAGACC
CCGGATGAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGC CACGGTGC CCGCCACCC GCGACGACGT
CCCCAGGGC GTACGCACC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGT CACCGAGCT CAAGAACTCT TCCTCACGG CGTCGGGCTC GACATCGGCA
AGGTGTGGT CGCGGACGAC GGCGCCCGG TGGCGTCTG GACCAGCCG GAGAGCGTCG AAGCGGGGGC
GGTGTTCGC GAGATCGGC CGCGCATGG CGAGTTGAGC GGTTCGGG TGGCCCGCA GCAACAGATG
GAAGCCCTC TGCGCCGCA CCGGCCAAG GAGCCCGCT GTTCTCTGG CACCCTCGG GTCTCGCCG
ACCACCAGG CAAGGTCTG GGCAGCGCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTT CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAG GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAAACTTGT
TTATTGCAG TTATAATGG TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTT
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGA TCTTAATAA TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```



Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

RefSeq: [NM_000447](#), [NM_012486](#)

UniProt ID: [P49810](#)

Synonyms: AD3L; AD4; CMD1V; PS2; STM2

Summary: Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act as protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]

Product images:

